Mölndal, Sweden

Thomas Peter Larsson

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Peter Larsson: Innovator in Pharmaceutical Chemistry

Introduction

Thomas Peter Larsson is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds that may aid in the treatment of various diseases. His work exemplifies the intersection of science and innovation, showcasing the importance of research in improving healthcare outcomes.

Latest Patents

Larsson holds a patent for a compound titled "Crystalline forms of N-[2-[[[2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide." This patent describes crystalline forms of the compound, which may be beneficial in modulating chemokine receptor activity, a crucial aspect in treating various diseases and conditions.

Career Highlights

Throughout his career, Thomas Peter Larsson has been associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative drug development, contributing to the advancement of medical science and patient care.

Collaborations

Larsson has collaborated with several esteemed colleagues, including Britt Anne Ingela Gullberg and Jeffrey Paul Stonehouse. These collaborations have fostered a productive environment for research and innovation, leading to significant advancements in their respective fields.

Conclusion

Thomas Peter Larsson's contributions to pharmaceutical chemistry and his innovative patent highlight the vital role of inventors in advancing healthcare solutions. His work continues to inspire future innovations in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…